Discovery is in our nature
Introducing the next generation of neurological medicine
We have designed, synthesized and tested a vast library of novel psychoplastogenic compounds that selectively target serotonin receptors to enable the treatment of multiple neurological diseases and disorders.
PsiloSterics | About Us
Moving Beyond SSRIs
Selective serotonin reuptake inhibitors (SSRIs) treat depression by increasing levels of serotonin in the brain. SSRIs block the reabsorption (reuptake) of serotonin into neurons. This makes more serotonin available to improve transmission of messages between neurons. However, SSRIs suffer from a variety of drawbacks, including the need for continuous dosing, poor response rates, and undesirable side effects (headache, nausea, insomnia, sexual dysfunction, increased suicide risk).
Latest From The Blog
PsiloSterics’ first Patent Application is Published
PsiloSterics | Our Approach
Selective
Psychoplastogens
Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Unlike SSRIs, our novel psychoplastogenic compounds bind directly to select serotonin receptors to activate and enhance neuronal transmission and aid in therapeutic biological processes.
ADVANTAGES OF THIS OPPORTUNITY
The Opportunity Ahead
Selective psychoplastogenic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists are not optimized for continual therapeutic use due to known negative side effects. Our novel therapeutics are designed to reduce or eliminate these known off-target side effects, potentially making them attractive candidates for widespread adoption for a large number of therapeutic indications.
